ASMB SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K/A

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Pipeline Updates

Aug 14, 2026

8-K

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Pipeline Updates

Aug 13, 2026

8-K

Assembly Biosciences, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 5, 2026

8-K

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

May 26, 2026

8-K

Assembly Biosciences Expands ABI-6250 Clinical Development into Cholestatic Liver Diseases

May 22, 2026

8-K

Assembly Biosciences Reports First Quarter 2026 Financial Results and Pipeline Progress

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

May 22, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Guggenheim Securities

May 22, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 6,980,811

Nov 21, 2025

424B5

REGISTERED OFFERING

Aug 11, 2025

424B5

PENDING FIXED PRICE OFFERING

Aug 11, 2025

424B5

ATM | Offering amount: $75,000,000

Nov 7, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 20, 2026

S-3

March 2026 SHELF

Mar 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2026

S-3

SHARE RESALE REGISTRATION

Oct 14, 2025

S-3MEF

August 2025 SHELF

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Bjorkquist Jeanette M (Reporting)

Nov 3, 2026

White Nicole S (Reporting)

Nov 3, 2026

Delaney William E IV (Reporting)

Nov 3, 2026

Gaggar Anuj (Reporting)

Nov 3, 2026

Okazaki Jason A (Reporting)

Nov 3, 2026

144

Form 144 - Report of proposed sale of securities

Nov 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 30, 2026

CORRESP

Form CORRESP - Correspondence

Mar 25, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 24, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 24, 2025

CORRESP

Form CORRESP - Correspondence

Nov 19, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 2, 2025

Assembly Biosciences, Inc. ASMB · SEC Filings